Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock
Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital age, CDER director says, challenging industry, regulators and others to creatively think about how to move away from legacy, paper-based processes in clinical trials and regulatory submissions.
You may also be interested in...
The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.
Acting FDA commissioner says there are a lot of strong forces in the research and pharma industries that could curb efforts to make pandemic-related clinical trial reforms permanent.
US FDA commissioner-nominee Califf calls for streamlining clinical trial bureaucracy, as well as open access to clinical data.